Clinical Trial Update: Phase 1/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants [Phase 1, Phase 2]

View source ↗

Summary

This update confirms completion of a Phase 1/2 study evaluating the safety and immunogenicity of the AERAS-404 vaccine in BCG-primed infants for tuberculosis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tuberculosis

Drugs mentioned

• AERAS 404

Snippet

Sponsor: Aeras | Conditions: Tuberculosis | Phase 1, Phase 2 | Status: COMPLETED